A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

This study is about a new medicine called vepdegestrant, which is being tested to help people with a type of breast cancer known as ER+/HER2 positive. Cells in this type of breast cancer have certain features (receptors) that the new medicine is designed to target.

The main goal of this particular study is not to see if the new medicine treats cancer directly, but to understand something very important about how it works inside the body. Researchers want to know if taking vepdegestrant changes how your body handles another common medicine called midazolam. Midazolam is often given when you need to relax before surgery or other medical procedures. Understanding how these two medicines interact is crucial because it helps doctors know if vepdegestrant might affect other medications a patient could be taking, making sure treatments are as safe and effective as possible.

This kind of research is a very early step in developing new medicines. It’s part of what’s called a 'Phase I' study, which typically focuses on how a new medicine moves through the body, how it's broken down, and how it leaves the body. This information is vital for future, larger studies that will look at whether the medicine actually treats the cancer itself.